Fennec Pharmaceuticals Inc. (FENC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
PO BOX 13628 RESEARCH TRIANGLE PARK, NC 27709 |
| State of Incorp. | BC |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 26,634 | 13,269 | 23,774 | 21,100 | 30,344 | 13,650 | |||
| Cash and cash equivalent | 26,634 | 13,269 | 23,774 | 21,100 | 30,344 | 13,650 | |||
| Receivables | (3,803) | (300) | |||||||
| Prepaid expense | 3,080 | 2,575 | 770 | 1,034 | 797 | 226 | |||
| Other current assets | 466 | 44 | 63 | 253 | 276 | 8 | |||
| Other undisclosed current assets | 17,747 | 11,270 | 2,121 | ||||||
| Total current assets: | 44,124 | 26,858 | 26,728 | 22,387 | 31,417 | 13,884 | |||
| Noncurrent Assets | |||||||||
| Long-term investments and receivables | |||||||||
| Accounts and financing receivable, after allowance for credit loss | |||||||||
| Other noncurrent assets | 2,438 | ||||||||
| Other undisclosed noncurrent assets | (1,616) | 6 | 211 | 27 | 262 | ||||
| Total noncurrent assets: | 822 | 6 | 211 | 27 | 262 | ||||
| TOTAL ASSETS: | 44,946 | 26,864 | 26,939 | 22,414 | 31,417 | 14,146 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 6,669 | 7,532 | 4,609 | 1,654 | 2,347 | 2,271 | |||
| Accounts payable | 3,241 | 3,778 | 2,390 | 777 | 1,571 | 1,612 | |||
| Accrued liabilities | 3,428 | 3,754 | 2,219 | 877 | 776 | 659 | |||
| Deferred revenue | 248 | ||||||||
| Other undisclosed current liabilities | 2 | 21 | |||||||
| Total current liabilities: | 6,919 | 7,553 | 4,609 | 1,654 | 2,347 | 2,271 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 24,561 | 2 | |||||||
| Deferred revenue | 24,561 | ||||||||
| Operating lease, liability | 2 | ||||||||
| Other undisclosed noncurrent liabilities | 19,338 | 30,931 | 24,899 | 4,988 | |||||
| Total noncurrent liabilities: | 43,899 | 30,933 | 24,899 | 4,988 | |||||
| Total liabilities: | 50,818 | 38,486 | 29,508 | 6,642 | 2,347 | 2,271 | |||
| Equity | |||||||||
| Equity, attributable to parent | (5,872) | (11,622) | (2,569) | 15,772 | 29,070 | 11,875 | |||
| Common stock | 145,608 | 144,307 | 142,591 | 140,801 | 140,733 | 106,392 | |||
| Additional paid in capital | 66,958 | 62,073 | 56,797 | 53,214 | 49,234 | 48,271 | |||
| Accumulated other comprehensive income | 1,243 | 1,243 | 1,243 | 1,243 | 1,243 | 1,243 | |||
| Accumulated deficit | (219,681) | (219,245) | (203,200) | (179,486) | (162,140) | (144,031) | |||
| Total equity: | (5,872) | (11,622) | (2,569) | 15,772 | 29,070 | 11,875 | |||
| TOTAL LIABILITIES AND EQUITY: | 44,946 | 26,864 | 26,939 | 22,414 | 31,417 | 14,146 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 47,538 | 21,252 | ||||||
| Cost of revenue (Cost of Product and Service Sold) | (517) | (1,259) | (86) | |||||
| Other undisclosed gross profit | 1,535 | |||||||
| Gross profit: | 47,021 | 19,993 | 1,449 | |||||
| Operating expenses | (44,970) | (32,764) | (24,038) | (17,223) | (18,055) | (13,009) | ||
| Other undisclosed operating income | 517 | 170 | ||||||
| Operating income (loss): | 2,568 | (12,771) | (22,589) | (17,223) | (17,885) | (13,009) | ||
| Nonoperating income (expense) | (2,639) | (3,274) | (1,125) | (123) | (224) | 234 | ||
| Investment income, nonoperating | 1,682 | 195 | 54 | 87 | 315 | |||
| Interest and debt expense | (4,069) | (402) | (64) | |||||
| Loss from continuing operations before equity method investments, income taxes: | (4,140) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
| Other undisclosed income from continuing operations before income taxes | 4,069 | |||||||
| Loss from continuing operations before income taxes: | (71) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
| Income tax expense | (365) | |||||||
| Other undisclosed loss from continuing operations | ||||||||
| Loss from continuing operations: | (436) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (17,346) | (18,511) | (12,839) | |
| Other undisclosed net loss | ||||||||
| Net loss: | (436) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
| Other undisclosed net income attributable to parent | 402 | 64 | ||||||
| Net loss available to common stockholders, diluted: | (436) | (16,045) | (23,714) | (17,346) | (18,109) | (12,775) | ||
Comprehensive Income ($ in thousands)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (436) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
| Comprehensive loss, net of tax, attributable to parent: | (436) | (16,045) | (23,714) | (17,346) | (18,511) | (12,839) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.